Food - Health

PR Newswire

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

  • Written by PR Newswire
RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB
  • Radiopharm will shortly initiate a PD-L1 Phase 1 therapeutic study in Australia in patients with NSCLC
  • Radiopharm acquired from NanoMab, Ltd. worldwide rights to PD-L1 technology for therapeutic use, as well as to imaging rights in China

MELBOURNE, Australia, Aug. 4, 2022 /PRNewswire/ -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the...